Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 402 Rectal Neoplasms 151 Colonic Neoplasms 148 Pancreatic Neoplasms 111 Stomach Neoplasms 106 Neoplasm Metastasis 87 Neoplasms 74 Esophageal Neoplasms 59 Small Cell Lung Carcinoma 44 Neuroblastoma 42 Lung Neoplasms 42 Glioblastoma 38 Carcinoma, Non-Small-Cell Lung 37 Brain Neoplasms 33 Esophageal Squamous Cell Carcinoma 32 Unspecified Adult Solid Tumor, Protocol Specific 31 Glioma 31 Breast Neoplasms 28 Central Nervous System Neoplasms 27 Adenocarcinoma Of Esophagus 27 Sarcoma 26 Gliosarcoma 22 Astrocytoma 22 Rhabdomyosarcoma 21 Sarcoma, Ewing 18 Adenocarcinoma 18 Gastrointestinal Neoplasms 17 Oligodendroglioma 16 Recurrence 13 Medulloblastoma 13

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Irinotecan × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡